Left ventricular ejection fraction of < 20%: Too bad for MitraClip© ?
Sebastian BarthMartina B HautmannSebastian KerberFrank GietzenWilko ReentsMichael ZacherPhilipp HalbfassDaniel P GrieseBernhard SchiefferKarsten HammPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
By careful selection, even patients in the end stage of advanced LV dysfunction as the result of the underlying myogenic problem and the additional harmful effects of the high volume loading due to the FMR can exhibit significant clinical and hemodynamic improvement after MitraClip© therapy.
Keyphrases
- ejection fraction
- aortic stenosis
- mitral valve
- left ventricular
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- oxidative stress
- skeletal muscle
- acute myocardial infarction
- prognostic factors
- stem cells
- left atrial
- coronary artery disease
- acute coronary syndrome
- patient reported outcomes
- cardiac resynchronization therapy